



Patient enrolment completed in US clinical trial

- Fully independent trial with first results on track for Q3 2017
 - Subjects now fully recruited
- Results to assist with FDA approval process and US market entry

Perth, Australia & Malta – 29 March 2017 – Neurotech International Limited (ASX: NTI) (“Neurotech” or “the Company”), developer of quality medical solutions in the neuroscience space, is pleased to announce that subject recruitment has closed for the fully independent clinical trial in the United States for Mente Autism, its flagship device for children on the autism spectrum (**Clinical Trial**).

The Clinical Trial will progressively onboard subjects to Mente Autism over time, with all subjects expected to be included on the trial by the end of May 2017. All required devices have been shipped for the trial.

The Clinical Trial, which is being independently conducted by the Carrick Institute, is a randomised, double blind, placebo-controlled prospective clinical study. Its aim is to investigate Mente Autism as a therapy for children aged between 3 and 12 years on the autism spectrum.

Each trial per patient will take twelve weeks, with first results expected in the third quarter of 2017.

Neurotech’s founder and chief scientific officer, Dr Adrian Attard Trevisan, said: “We are excited that the Mente Autism technology is being used in this Clinical Trial, but to maintain the trial’s integrity, it is also important to note that Neurotech is not involved in the independent research investigations that are being conducted by the Carrick Institute. We are confident that the trial will reinforce Mente Autism’s positioning as a clinical-quality home-based therapy for children on the autism spectrum.”

The Clinical Trial is registered with the National Institutes of Health in the US under "Neurofeedback Therapy for Children Diagnosed with Autism" and identifier: NCT02773303. It can be accessed via the US Clinical Trials website at <https://clinicaltrials.gov/ct2/show/study?term=Mente&rank=2>.

For more information about Neurotech and Mente Autism please visit:

<http://www.neurotechinternational.com>.

<http://www.mentetech.com>.

-ends-

About Neurotech

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech’s primary mission is to improve the lives of people with neurological conditions, with a vision of becoming the global leader in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device Mente Autism and its associated platform,

Neurotech International Ltd

ABN 73 610 205 402

Level 14, 191 St Georges Terrace

Perth, Western Australia 6060

www.neurotechinternational.com

Neurotech is focused on the development and commercialisation of technological solutions for the diagnosis and treatment of such conditions, starting with autism. For more information, visit: <http://www.neurotechinternational.com>.

For more information please contact:

Matthew Wright
matt@nwrcommunications.com.au
Tel: +61 451 896 420